Chevy Chase Trust Holdings LLC Has $230.91 Million Stake in Johnson & Johnson (NYSE:JNJ)

Chevy Chase Trust Holdings LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,392,345 shares of the company's stock after selling 6,756 shares during the period. Johnson & Johnson comprises 0.7% of Chevy Chase Trust Holdings LLC's portfolio, making the stock its 19th largest holding. Chevy Chase Trust Holdings LLC owned approximately 0.06% of Johnson & Johnson worth $230,907,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. MRP Capital Investments LLC grew its holdings in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co lifted its position in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares during the last quarter. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after purchasing an additional 67 shares in the last quarter. Sage Mountain Advisors LLC increased its holdings in Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after buying an additional 67 shares during the last quarter. Finally, Sovereign Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Raymond James Financial dropped their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Down 0.0%

NYSE JNJ traded down $0.03 during trading hours on Thursday, reaching $152.25. 7,147,500 shares of the company's stock were exchanged, compared to its average volume of 9,171,523. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company's 50-day moving average is $153.95 and its two-hundred day moving average is $153.67. The company has a market capitalization of $366.33 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.42%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.